The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are \[18F\]DPA-714 and 18F-GE180. We hypothesize that \[18F\]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Participant received one injection of 200 MBq of \[18F\]DPA-714
Diagnostic performances of [18F]DPA-714 PET for glioma grading obtained by stereotactic biopsies of glioma
Sensitivity and specificity of \[18F\]DPA-714 PET using anatomopathological assessment of biopsies as gold standard
Time frame: [18F]DPA-714 PET performed up to 30 days before brain surgery
Comparison of [18F]DPA-714 PET quantitative parameters with anatomopathological assessment of the surgery specimen
Comparison of \[18F\]DPA-714 PET quantitative parameters with the histological types of gliomas, with the IDH1-mutational status, and the 1p19q codeletion status
Time frame: [18F]DPA-714 PET performed up to 30 days before brain surgery
Comparison of [18F]DPA-714 PET quantitative parameters with tumor microenvironment
Comparison of \[18F\]DPA-714 PET quantitative parameters with the frequency and phenotype of tumor microenvironment different glioma-associated cells
Time frame: [18F]DPA-714 PET performed up to 30 days before brain surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.